Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRAT | O95237 | 1/20 | 0.40 |
| ▸ | HOGA1 | Q86XE5 | 1/20 | 0.38 |
| ▸ | FBP1 | P09467 | 1/20 | 0.37 |
| ▸ | IDUA | P35475 | 1/20 | 0.37 |
| ▸ | GJA1 | P17302 | 1/20 | 0.35 |
| ▸ | GJB2 | P29033 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ADK | P55263 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.33 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.33 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.33 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3667992 | 0.97 | LRAT (0.39) | LRATHOGA1FBP1IDUAGJA1 | |
| SCHEMBL30228797 | 0.97 | IDUA (0.40) | LRATHOGA1FBP1IDUAGJA1 | |
| SCHEMBL12301700 | 0.89 | LGALS1 (0.48) | GJA1GJB2MEN1CYP2C9TSHR | |
| SCHEMBL13437007 | 0.87 | LGALS1 (0.52) | GJA1GJB2MEN1CYP2C9TSHR | |
| SCHEMBL22618254 | 0.87 | LGALS1 (0.52) | GJA1GJB2MEN1CYP2C9TSHR | |
| SCHEMBL6473412 | 0.87 | LGALS1 (0.52) | GJA1GJB2MEN1CYP2C9TSHR | |
| SCHEMBL13437028 | 0.87 | LGALS1 (0.52) | GJA1GJB2MEN1CYP2C9TSHR | |
| SCHEMBL278868 | 0.87 | LGALS1 (0.52) | GJA1GJB2MEN1CYP2C9TSHR | |
| SCHEMBL18805899 | 0.87 | HOGA1 (0.40) | LRATHOGA1FBP1IDUAGJA1 | |
| SCHEMBL6477822 | 0.87 | LGALS1 (0.52) | GJA1GJB2MEN1CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090098145-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | SIRION THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090098145-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | SIRION THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090098145-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | SIRION THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| EP-2037951-A2 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | Sirion Therapeutics, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007150046-A2 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | SIRION THERAPEUTICS, INC (US) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007150046-A2 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | SIRION THERAPEUTICS, INC (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098145-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | ALDH1A2, PDE6C, EYA2 | LRAT 55/4885HOGA1 1468/4885FBP1 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.